Pulmonary arterial hypertension
Conditions
Interventions
None listed
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Diagnosed with pulmonary hypertension (ICD code: I27.0): (1) Idiopathic pulmonary arterial hypertension (IPAH); (2) Hereditary pulmonary arterial hypertension (HPAH); (3) Drug and poison related pulmonary hypertension; (4) Disease-related pulmonary hypertension: 1) Connective tissue disease (CTD); 2) Congenital heart disease; 3) Age >= 18 years old at the time of first treatment with Selexipag tablets; 2. The patient has used Selexipag tablets for >= 90 days, and has dose titration records (all recorded dose changes, including but not limited to: starting dose and date and maximum tolerated dose and date); 3. WHO functional classification II and III.
Exclusion criteria
Exclusion criteria: 1. Pulmonary hypertension patients with PAHWHO function grade IV; 2. Pulmonary hypertension with pulmonary veno-occlusive disease (PVOD)/pulmonary capillary haemangiomatosis (PCH); 3. Patients with moderate or severe obstructive pulmonary disease; 4. Patients with moderate or severe restrictive lung disease; 5. Patients with moderate or severe liver damage (Child-Pugh classification B and C); 6. Patients with left ventricular dysfunction; 7. Patients with severe renal insufficiency; 8. Patients with severe cardiovascular disease (coronary heart disease or unstable angina, myocardial infarction in the last 6 months, decompensated heart failure without close monitoring, severe arrhythmia); 9. Cerebrovascular events (such as transient ischemic attack, stroke) occurred within 3 months before enrollment; 10. Congenital or acquired valve defects related to myocardial functional diseases and not related to pulmonary hypertension; 11. Combined use of strong CYP2C8 inhibitors (such as gemfibrozil); 12. Patients who have used Selexipag tablets in the past and have stopped using them (before the study) or patients who have used Selexipag tablets in clinical trials before; 13. Those who have participated in clinical trials within one month before enrollment; 14. Those who are known to be allergic to the study drug or similar drugs, or have a history of allergic diseases or allergic constitution; 15. Female patients during lactation and pregnancy; 16. Patients with incomplete key clinical data, or other factors considered by the investigator to be unsuitable for participating in this study; 17. Patients with other primary malignant tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| French Pulmonary Hypertension Network (FPHN) non-invasive risk stratification; | — |
Secondary
| Measure | Time frame |
|---|---|
| WHO Functional class;N-terminal pro-B-type natriuretic peptide;6-minute walking distance;right atrial area;right ventricular diameter;Tricuspid Annular Plane Systolic Excursion (TAPSE);dosage and side effect; | — |
Countries
China
Contacts
Public ContactQiushang Ji
Qilu Hospital of Shandong University
Outcome results
None listed